Clinical trials: Diabetes Mellitus, Type I
Type I Diabetes
Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)
Background: Type 1 diabetes (T1D) is a common chronic disease in children, occurring in approximately 1 of every 400 to 600 children.
- Trial name
- NCT00999375
- Testing
- Education, Problem Solving, Social Learning
- Where
- United States
- Volunteers
- 293 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Diabetes Mellitus, Type 1
Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting
This is a feasibility study of an artificial pancreas (AP) system with our previously validated Zone-MPC and Health Monitoring System (HMS) algorithms (ClinicalTraisl.gov: NCT01929798) integrated into the Diabetes Assistant…
- Trial name
- NCT02463682
- Testing
- CGM and Insulin Pump, Closed-Loop Control System
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sansum Diabetes Research Institute
Type 1 Diabetes, Type 2 Diabetes
Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus
To evaluate the efficacy of arginase inhibition on endothelial function in patients with type 1 diabetes and type 2 diabetes.
- Trial name
- NCT05806502
- Testing
- Nω-hydroxy-nor-arginine
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 1, Bone Fracture
Prevalence of Vertebral Fractures in Patients With Type 1 Diabetes
Background : Type 1 diabetes is associated with an increased risk of fractures. The mechanisms accounting for this bone fragility are not yet fully understood.
- Conditions
- Diabetes Mellitus, Type 1, Bone Fracture, Bone Health
- Trial name
- DenSiFy (NCT04064437)
- Testing
- Clinical tests, Biochemical tests, DXA scan
- Where
- 2 sites in Canada
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Nephropathy, Hypoxia
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes.
- Conditions
- Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes
- Trial name
- Astronaut (NCT04193566)
- Testing
- Forxiga
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes Mellitus, Type 1
SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1
Primary objective: To compare metabolic control as measured by Blood Glucose (BG) upon arising from bed (7:00 am - 12:00 pm) in type 1 Diabetes mellitus patients who skip the morning meal during treatment with MDI basal/bolus…
- Trial name
- NCT00313937
- Testing
- Insulin glargine
- Where
- Germany
- Volunteers
- 91 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus, Hypoglycemia
24/7 Closed-loop in Older Subjects With Type 1 Diabetes
The main objective of this open-label, multi-centre, randomised, crossover design study is to determine whether automated day and night closed-loop insulin delivery for 16 weeks under free living conditions is safer and more…
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia, Arrythmia
- Trial name
- DAN06 (NCT04025762)
- Testing
- Hybrid closed-loop system (CamAPS FX), Sensor augmented pump therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- University of Cambridge
Type 1 Diabetes
Psychological Aspects and Insulin Pump Therapy
The Continuous Subcutaneous Insulin Infusion (CSII) might have an impact on psychological distress and some psychological factors might be predictors of metabolic control; however, very few studies conducted so far were…
- Trial name
- NCT02138188
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Universita di Verona
Diabetes
Effect of Glucose on QTc Interval in Type 1 Diabetes
High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have both been shown independently to affect heart activity in healthy volunteers as recorded by ECG. i.e.
- Trial name
- NCT01984827
- Testing
- Moxifloxacin, hyper-glycaemic clamp
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richmond Research Institute
Diabetes Mellitus (Type 1 and Type 2)
Socio-Ecological Determinants and Health Literacy: A Path Analysis of Self-Management Agency Among Patients With Diabetes Mellitus
This study aims to examine the relationships between socio-ecological determinants, health literacy, and self-management agency among patients with diabetes mellitus.
- Trial name
- NCT07591103
- Testing
- Questionnaire-based assessment
- Where
- 2 sites in Egypt
- Volunteers
- 400 people
- Sponsor
- Alexandria University
Type 1 Diabetes
Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care
Adolescence and young adulthood may be particularly stressful developmental periods due to the numerous transitions into new roles and the need for increased independence.
- Trial name
- T1D (NCT02760303)
- Testing
- Cognitive Behavioral Therapy, Mindfulness Based Stress Reduction, Diabetes Support and Education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Wayne State University
Type 1 Diabetes Mellitus, Lipohypertrophy
Innovative Insulin Injection Sites Map to Minimize Lipohypertrophy Risk
Background: Patients on long-term insulin therapy frequently develop a condition called lipohypertrophy (LH), which involves the accumulation of abnormal fatty tissue at insulin injection sites.
- Trial name
- NCT07561086
- Testing
- Insulin Injection Site Mapping Tool
- Where
- Egypt
- Volunteers
- 170 people
- Sponsor
- Helwan University
Type 1 Diabetes, Diabetes, Autoimmune
Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study
Type 1 diabetes has been poorly characterised, with very sparse information available in the literature about the characteristics of the disease in Africa.
- Trial name
- YODA (NCT05013346)
- Testing
- No intervention needed
- Where
- 4 sites in Cameroon, South Africa and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Yaounde Central Hospital
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels
To determine if patients with a history of Diabetes Mellitus Type I or II developed a change in blood glucose levels as reported on Continuous glucose monitoring devices (CGMS) within the first week following administration of…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
- Trial name
- NCT04923386
- Testing
- None (not interventional)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Levenson, David I., M.D.
TYPE 1 DIABETES
β-cell Function in Type 1 Diabetes May Not Be As Low As Presumed
Enhancing endogenous insulin production in type 1 diabetic patients (T1DP) can improve glycemic control and decrease complications and rates of mortality.
- Trial name
- NCT02199470
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people
- Sponsor
- Gonca Incemehmet Tamer
Type 1 Diabetes Mellitus
Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus
Each subject will be randomly allocated to a sequence of two treatments applied at two separate dosing visits. At each dosing visit subjects will be injected with individualised doses of either BioChaperone® Combo or Humalog® Mix…
- Trial name
- NCT02514954
- Testing
- Biochaperone® Combo, Humalog® Mix25
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 1
Apelin as a Marker of Early Complications in Type 1 Diabetes Mellitus
Aims of the Research : 1. assessment of serum apelin levels in patients with T1DM with comparison to non-diabetic controls. 2. investigate the relation between serum apelin levels and glycemic balance. 3.
- Trial name
- NCT05738577
- Volunteers
- 90 people
- Sponsor
- Assiut University
Pregnancy in Diabetic, Type 1 Diabetes
Maternal ExeRcIse Timing to Optimise Postprandial Glucose in Type 1 Diabetes
Poor glycaemic control in pregnancy is a major factor leading to obstetric complications and future maternal-offspring diseases.
- Trial name
- MERIT1D (NCT05843175)
- Testing
- Exercise and meal testing (acute stimuli)
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- University of Graz
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
The aim of this trial is to demonstrate bioequivalence of Wosulin R to Actrapid with regard to its total and to its maximum serum insulin concentrations.
- Trial name
- NCT00752180
- Testing
- Wosulin R, Actrapid
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wockhardt
Diabetes Mellitus, Type 1
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.
- Trial name
- ONWARDS 6 (NCT04848480)
- Testing
- insulin icodec, insulin degludec, insulin aspart
- Where
- 130 sites in United States, Austria and 10 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.